- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00753766
Multifactorial Pre-operative Intervention in Diabetes Mellitus
Multifactorial Pre-Operative Intervention in Diabetes Mellitus
Studienübersicht
Status
Intervention / Behandlung
Detaillierte Beschreibung
Patients with diabetes that require hospitalization are at increased risk for morbidity and mortality, especially when undergoing surgery. There is some evidence that intensive glucose management during hospitalization may improve outcomes. However, no studies have evaluated intensive diabetes treatment before hospitalization.
Preliminary data from patients having vascular surgery show that those with diabetes have longer hospital stays, more frequent wound infections, and are more likely to require a return to the operating room when compared to patients without diabetes. In particular, insulin-treated patients have even greater peri-operative complications than non-insulin treated patients with diabetes. However, these data also suggest that a clinical trial to test the hypothesis that pre-operative intensive management has significant impact on peri-operative complications would require a very large number of participants to have adequate power.
Thus, our objective is to conduct a pilot and feasibility study to determine whether an intervention that involves intensive pre-operative diabetes management can be successfully implemented and to assess whether trends for benefit are observed. The results of this trial will support the conduct of a definitive study that tests the effectiveness of such an intervention in a larger sample of patients.
This is a randomized, parallel group clinical trial in insulin-treated patients with diabetes mellitus who have been scheduled for elective vascular surgery. We will randomize 46 participants diabetes mellitus: insulin-treated with HbA1c 7.5% or treated with oral agents with an elevated HbA1c who are scheduled for vascular surgery and in whom a 6 week pre-operative delay poses no substantial medical risks, as determined by the staff surgeon. We will exclude individuals with markedly elevated HbA1c or blood pressure; those with recently manifest cardiovascular disease, and those unable to attend regularly scheduled follow-up visits during the pre-operative period.
Participants will be randomized to either continue with usual care or participate in a multifactorial intervention conducted over a 6-week period. During the intervention period, participants will meet with a care manager and/or endocrinologist on at least 3 occasions and have telephone follow-up between these visits. They will receive instruction on lifestyle modifications; measure glucose and blood pressure at home (including the use of a continuous glucose monitoring device on 2 occasions), and receive care management to optimize glucose, blood pressure, and lipid lowering, as appropriate.
The primary outcome measure is the percent of screened participants that are eligible and choose participation Secondary end points will include: participant adherence with the study protocol, change from baseline in A1c and fructosamine, occurrence of wound infections in the 30-day peri-operative period, a composite of death from cardiovascular causes, non-fatal myocardial infarction, coronary artery bypass grafting, percutaneous coronary intervention, nonfatal stroke, or amputation as a result of peripheral ischemia; length of hospital stay; and rate of return to the operating room.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Unzutreffend
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
- Kind
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Diagnosis of diabetes mellitus
- A1c 7.5%,
- Scheduled elective vascular surgery that may be safely deferred for 6 weeks
- Surgeon's approval to participate
Exclusion Criteria:
- Hemoglobin A1c >14% (This criterion was included since, once identified, such a patient warrants improved glucose control and can not be ethically entered into a trial where there is a 50% chance of being assigned to usual care)
- Myocardial infarction in prior 6 months
- Cerebrovascular disease in prior 6 months
- Active cancer requiring ongoing treatment
- Severe psychiatric disease limiting ability to comply with protocol
- Unable to attend follow up appointments
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Kein Eingriff: Übliche Pflege
Kontrollgruppe
|
|
Experimental: Multifactorial Intervention
Mulitfactorial intervention - addressing glucose, blood pressure, lipids, smoking, nutrition and exercise.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
---|---|
Percent of Screened Participants That Are Eligible and Choose Participation
Zeitfenster: 6 weeks
|
6 weeks
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Percentage of Participants With Full Adherence to the Study Protocol (i.e. Attending Study Visits, CGMS Studies)
Zeitfenster: 6 weeks
|
6 weeks
|
|
Percentage of Participants Not Completing the Protocol Due to the Need for Urgent Surgery and/or Treatment-related Complications
Zeitfenster: 6 weeks
|
6 weeks
|
|
Change in A1c From Baseline to Pre-admission (A1c is the Standard Parameter to Assess Chronic Glucose Control])
Zeitfenster: 6 weeks
|
A1c measured at two time points - baseline and 6 weeks later (pre-admission).
This parameter is the difference between those two time points.
|
6 weeks
|
Number of Participants With Occurrence of Wound Infection in the 30 Day Post-operative Period
Zeitfenster: 30 days
|
30 days
|
|
Length of Hospital Stay
Zeitfenster: 6 weeks
|
6 weeks
|
|
Number of Participants Who Experience a Composite of Death From Cardiovascular Cause, Non-fatal Myocardial Infarction, Coronary Artery Bypass Grafting, Percutaneous Coronary Intervention, Nonfatal Stroke, or Amputation as a Result of Peripheral Ischemia
Zeitfenster: 6 weeks
|
6 weeks
|
|
Percentage of Participants Who Need to Return to the Operating Room
Zeitfenster: 6 weeks
|
6 weeks
|
Mitarbeiter und Ermittler
Ermittler
- Hauptermittler: Paul R. Conlin, MD, VA Boston Healthcare System West Roxbury Campus, West Roxbury, MA
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- CLIN-004-04F
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Diabetes Mellitus
-
Medical College of WisconsinMedical University of South CarolinaAbgeschlossenDiabetes Mellitus | Typ 2 Diabetes mellitus | Altersdiabetes mellitus | Nicht insulinabhängiger Diabetes mellitus | Nicht insulinabhängiger Diabetes Mellitus, Typ IIVereinigte Staaten
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.AbgeschlossenDiabetes mellitus, Typ 1 | Diabetes Typ 1 | Diabetes Typ1 | Diabetes mellitus Typ 1 | Autoimmundiabetes | Diabetes mellitus, insulinabhängig | Jugenddiabetes | Diabetes, Autoimmun | Insulinabhängiger Diabetes mellitus 1 | Diabetes mellitus, insulinabhängig, 1 | Diabetes mellitus, spröde | Diabetes mellitus... und andere BedingungenVereinigte Staaten
-
SanofiAbgeschlossenDiabetes mellitus Typ 1 – Diabetes mellitus Typ 2Ungarn, Russische Föderation, Deutschland, Polen, Japan, Vereinigte Staaten, Finnland
-
Guang NingRekrutierungTyp 2 Diabetes mellitus | Diabetes mellitus Typ1 | Monogenetischer Diabetes | Pankreatogener Diabetes | Medikamenteninduzierter Diabetes mellitus | Andere Formen von Diabetes mellitusChina
-
Meir Medical CenterAbgeschlossenDiabetes mellitus Typ 2 | Diabetes mellitus, nicht insulinabhängig | Diabetes mellitus, zur oralen hypoglykämischen Behandlung | Diabetes mellitus vom ErwachsenentypIsrael
-
Hanmi Pharmaceutical Company LimitedUnbekanntTyp 2 Diabetes mellitus | Diabetes mellitus Typ1Vereinigte Staaten
-
Joslin Diabetes CenterCambridge Medical Technologies, LLCAbgeschlossenTyp 2 Diabetes mellitus | Diabetes mellitus Typ1Vereinigte Staaten
-
Hoffmann-La RocheRoche DiagnosticsAbgeschlossenDiabetes mellitus Typ 2, Diabetes mellitus Typ 1Deutschland
-
Leiden University Medical CenterAndaluz Health ServiceAbgeschlossenDiabetes Mellitus | Gesundheitsverhalten | Selbstwirksamkeit | Typ 2 Diabetes mellitus | Diabetes mellitus Typ1Niederlande, Spanien
-
Medical University of South CarolinaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)AbgeschlossenDiabetes mellitus, Typ 2 | Diabetes mellitus, Typ II | Diabetes mellitus, Beginn im Erwachsenenalter | Diabetes mellitus, nicht insulinabhängig | Diabetes mellitus, nicht insulinabhängigVereinigte Staaten
Klinische Studien zur Multifactorial Intervention
-
University of FloridaAbgeschlossenEmpfindlichkeitVereinigte Staaten
-
Case Western Reserve UniversityAmerican University; Purdue UniversityRekrutierung
-
Thomas Jefferson UniversityRekrutierungProstatakarzinomVereinigte Staaten
-
Rabin Medical CenterAcademic College of Tel Aviv-Jaffa; Israel Cancer AssociationUnbekanntEierstockkrebs | Krebs des Gebärmutterhalses | Krebs des EndometriumsIsrael
-
Biolux Research Holdings, Inc.BeendetKieferorthopädische ZahnbewegungKanada
-
University of Kansas Medical CenterAbgeschlossen
-
German Institute of Human NutritionBeneo GmbHAbgeschlossenDiabetes mellitus, Typ 2 | Metabolisches SyndromDeutschland
-
University of WashingtonNational Cancer Institute (NCI)AbgeschlossenMelanom | Lymphom | Gebärmutterhalskrebs | Leukämie | Brustkrebs | Darmkrebs | Darmkrebs | Bösartige NeubildungVereinigte Staaten
-
University MariborAktiv, nicht rekrutierendHerzkrankheiten | Herz-Kreislauf-Erkrankungen | Koronare Herzkrankheit | Koronare Herzerkrankung | Lebensstil | Kontinuierliche Glukoseüberwachung | Verhaltensänderung | CGM | Visuelle AnalyseSlowenien
-
Columbia UniversityNational Institute on Drug Abuse (NIDA)AbgeschlossenHIV | Sexuell übertragbare InfektionenVereinigte Staaten